A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Key Who May Qualify: - Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening. - Has adequate organ and marrow function as defined in protocol. - Measurable disease as per RECIST v1.1. - You should be able to carry out daily activities with 0 level of ability (ECOG 0)-1. - Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except alopecia and Grade 2 peripheral neuropathy. - HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol. Key Who Should NOT Join This Trial: - Has known active cancer that has spread to the brain and/or carcinomatous meningitis. - An active second malignancy. - Has active or a known history of Hepatitis B or known active Hepatitis C virus infection. - Has active tuberculosis or has a known history of active tuberculosis. - Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration. - History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis. - Has an active autoimmune conditions (where your immune system attacks your own body) that has required systemic treatment in past 2 years. - Previous immunotherapies related to mode of action of GI-102. - Has a diagnosis of weakened immune system or is receiving chronic systemic steroid therapy or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day 1. - Administration of prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment. - Radiotherapy within the last 2 weeks before start of study treatment administration, with exception of limited field palliative radiotherapy. - Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1. ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.